ExitHealthcare
Siegfried Holding acquires Noramco, Extractas and Purisys from SK Capital
The deal gives the Swiss CDMO a North American controlled-substance API manufacturing footprint, while SK Capital holds onto finished-dose maker Halo Pharmaceuticals.
- Target
- Noramco, Extractas Biosciences and Purisys
- Seller
- SK Capital
- Source
- PE Hub